

FOLEY & LARDNER LLP  
ATTORNEYS AT LAWRECEIVED  
CENTRAL FAX CENTER

JUN 28 2004

## FACSIMILE TRANSMISSION

Total # of Pages 25 (including this page)

OFFICIAL

TO:	PHONE:	FAX #:
Examiner Sheela J. Huff USPTO	571-272-0834	571-273-0834

From: Michele M. Simkin, Esq.  
Sender's Direct Dial: (202) 672-5538  
Date: June 28, 2004  
U.S. Appl. No. 10/061,690  
U.S. Appl. No. 10/348,713  
U.S. Appl. No. 09/978,242 \*  
Client/Matter No: U.S. Appl. No. 10/023,929  
U.S. Appl. No. 09/967,736  
U.S. Appl. No. 10/020,618

## MESSAGE:

## CERTIFICATION

I hereby certify that this Revocation of Power of Attorneys and Appointment of New Attorneys along with Letters of Express Abandonment are being facsimile transmitted to U.S. Patent and Trademark Office on the date shown below.

June 28, 2004  
Date

Heidi Hernandez  
Heidi V. Hernandez

If there are any problems with this transmission or if you have not received all of the pages, please call 202-672-5576.

Operator:	Time Sent:	Return Original To:
		Heidi V. Hernandez

CONFIDENTIALITY NOTICE: THE INFORMATION CONTAINED IN THIS FACSIMILE MESSAGE IS INTENDED ONLY FOR THE PERSONAL AND CONFIDENTIAL USE OF THE DESIGNATED RECIPIENTS NAMED ABOVE. THIS MESSAGE MAY BE AN ATTORNEY-CLIENT COMMUNICATION, AND AS SUCH IS PRIVILEGED AND CONFIDENTIAL. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT OR ANY AGENT RESPONSIBLE FOR DELIVERING IT TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT YOU HAVE RECEIVED THIS DOCUMENT IN ERROR, AND THAT ANY REVIEW, DISSEMINATION, DISTRIBUTION OR COPYING OF THIS MESSAGE IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, PLEASE NOTIFY US IMMEDIATELY BY TELEPHONE AND RETURN THE ORIGINAL MESSAGE TO US BY MAIL. THANK YOU.

RECEIVED  
CENTRAL FAX CENTER

010

JUN 28 2004

OFFICIAL

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**  
**ATTORNEY DOCKET NO. 039386-0101 (FORMERLY PF-0451-2 DIV)**

Applicant: Olga BANDMAN et al.  
Title: HUMAN NUCLEOLIN-LIKE PROTEIN  
Appl. No.: 09/978,242  
Filing Date: 10/15/2001  
Examiner: Sheela J. Huff  
Art Unit: 1642

**REVOCATION OF POWER OF ATTORNEY AND**  
**APPOINTMENT OF NEW ATTORNEYS**

Sir:

The undersigned has reviewed all the documents in the chain of title of the above-identified patent application and, to the best of undersigned's knowledge and belief, title is in the assignee identified below.

Incyte Corporation, formerly known as Incyte Genomics, Inc., also formerly known as Incyte Pharmaceuticals, Inc., having a principal place of business located at 3160 Porter Drive, Palo Alto, California 94304, certifies that it is the assignee and owner of the entire right, title and interest in, to, and under the invention described and claimed in the above-identified application by virtue of an Assignment recorded at Reel 009399, Frame 0972, hereby revokes all previous powers of attorney and appoints those practitioners under Customer No. 22428 as attorneys/ agents with full power of substitution to prosecute this application and to transact all business in the Patent and Trademark Office in connection therewith.

Atty. Dkt. No. 039386-0101  
(Formerly PF-0451-2 DIV)

Please direct all correspondence to:


Michele M. Simkin, Esq.  
Reg. No. 34,717  
Customer No.: 22428  
Foley & Lardner LLP  
Washington Harbour  
3000 K Street, N.W., Suite 500  
Washington, D.C. 20007-5109

and direct all telephone calls and facsimile transmissions to: Foley & Lardner LLP; Phone: Tel: (202) 672-5300 Fax: (202) 672-5399 The undersigned (whose title is supplied below) is empowered to act on behalf of the assignee.

I hereby declare that all statements made herein are of my own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine of imprisonment, or both, under Section 1001, Title 18, of the United States Code, and that such willful false statements may jeopardize the validity of the patent.

INCYTE CORPORATION

Date: April 28 2004

By:   
Patricia Anne Schreck  
Executive VP, General Counsel